Peritoneal dialysis solutions with polypeptides
AssigneeBaxter International Inc.
InventorsLeo Martis, Ron Burke, Dirk Faict
Life of this patent
Estimating the term…
Abstract
The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such as dextrose. To this end, the present invention provides, in an embodiment, a peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0% (w/v) polypeptides and approximately 0.5% to about 4.0% (w/v) dextrose. The polypeptides have well defined characteristics.
Claims18
A peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0% by weight of synthetic polypeptides wherein the synthetic peptides are approximately 2 to about 15 amino acids long.
A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:
- a first part housed in a first structure including approximately 1.0 to about 8% (w/v) dextrose and a pH of approximately 4.0 to about 5.5;
- a second part housed in a second structure including approximately 0.5 to about 8.0% (w/v) polypeptides and a pH of approximately 6.0 to about 7.5;
- and
- including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided:
- 120 to about 150 (mEq/L) sodium;
- 80.0 to about 110.0 (mEq/L) chloride;
- 0.0 to about 5.0 (mEq/L) lactate;
- 0.0 to about 45.0 (mEq/L) bicarbonate;
- 0.0 to about 4.0 (mEq/L) calcium;
- and 0.0 to about 4.0 (mEq/L) magnesium.
An intraperitoneal drug delivery solution comprising approximately 0.25 to about 4.0% (w/v) polypeptides.
A peritoneal dialysis solution comprising as osmotic agent:
- a synthetic polypeptide mixture having an average molecular weight of approximately 400 to about 900 daltons.
Dependencies are inferred from the claim text.